Novel vancomycin free base - Sterosomes for combating diseases caused by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus infections (S. Aureus and MRSA)

被引:0
作者
Nwabuife, Joshua C. [1 ]
Hassan, Daniel [1 ]
Pant, Amit Madhaorao [1 ]
Devnarain, Nikita [1 ]
Gafar, Mohammed Ali [1 ]
Osman, Nawras [1 ]
Rambharose, Sanjeev [2 ]
Govender, Thirumala [1 ]
机构
[1] Univ KwaZulu Natal, Coll Hlth Sci, Discipline Pharmaceut Sci, ZA-4000 Durban, South Africa
[2] Stellenbosch Univ, Fac Sci, Dept Physiol Sci, Bag X1 Matieland, ZA-7602 Stellenbosch, South Africa
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
Sterosomes; Novel delivery systems; Antimicrobial resistance; DRUG-DELIVERY SYSTEMS; IN-VITRO; NANOPARTICLES; ACID; NANOTECHNOLOGY; NANOSYSTEM; PATHOGENS; EFFICACY; POLYMER; BURDEN;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A clarion call to save antimicrobials is the need for the evolution of novel delivery systems to combat resistance posed by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus (S. aureus and MRSA) to con-ventional forms. Herein, we present a novel vancomycin free base - sterosomes (VCM-FB - Sterosomes) for vancomycin free base (VCM-FB) delivery against S. aureus and MRSA. VCM-FB - Sterosomes were prepared using the thin-film hydration method and were characterised physiochemically, in silico, in vitro and in vivo. In vitro cytotoxicity on MCF-7 and HEK-293 cell lines were evaluated, with results revealing cell viability above 70% after exposure to VCM-FB - Sterosomes, indicating biosafety. VCM-FB - Sterosomes had a hydrodynamic diameter, polydispersity index and surface-charge of 114.14 +/- 0.59 nm, 0.210 +/- 0.02 and +36.3 +/- 5.42 mV, respectively, with entrapment efficiency, drug loading and VCM-FB release after 48 h of 79.61 +/- 0.59%, 90.91% w/w and 54.95 +/- 9.75% respectively. In silico studies showed a self-assembly in five nano seconds, which was stable thereafter. VCM-FB - Sterosomes were seen to be stable over 90 days and were also non-hemolytic. VCM-FB - Sterosomes showed a 2-fold superior minimum inhibition efficiency (MIC) against S. aureus and MRSA, relative to bare VCM-FB, with MICs of 1.95 mu g/mL and 0.98 mu g/mL for VCM-FB and VCM-FB - Sterosomes (S. aureus), and 7.81 mu g/mL and 3.91 mu g/mL for VCM-FB and VCM-FB - Sterosomes (MRSA), respectively. A faster bacterial killing time was also recorded for VCM-FB - Sterosomes compared to bare VCM-FB. Greater MRSA membrane damage was indicated by an increase and decrease in electrical conductivity, and protein/DNA concentration, respectively. VCM-FB - Sterosomes showed superior MRSA biofilm reduction (27.22%) compared to VCM-FB (2.53%). In vivo BALB/c mice-infected skin model showed that VCM-FB - Sterosomes had significant MRSA eradication (27-fold) compared to bare VCM-FB (4-fold). These results amplify the superiority of VCM-FB - Sterosomes for S. aureus and MRSA infection treatment compared to conventional forms.
引用
收藏
页数:13
相关论文
共 77 条
  • [1] Antibacterial and antivirulence activities of auranofin against Clostridium difficile
    AbdelKhalek, Ahmed
    Abutaleb, Nader S.
    Mohammad, Haroon
    Seleem, Mohamed N.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 53 (01) : 54 - 62
  • [2] Adwan G, 2016, INT J MED RES HEALTH, V5, P75
  • [3] Synergistic Anti-MRSA Activity of Cationic Nanostructured Lipid Carriers in Combination With Oxacillin for Cutaneous Application
    Alalaiwe, Ahmed
    Wang, Pei-Wen
    Lu, Po-Liang
    Chen, Ya-Ping
    Fang, Jia-You
    Yang, Shih-Chun
    [J]. FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [4] Nanoparticles for treatment of bovine Staphylococcus aureus mastitis
    Algharib, Samah Attia
    Dawood, Ali
    Xie, Shuyu
    [J]. DRUG DELIVERY, 2020, 27 (01) : 292 - 308
  • [5] Anderson AS, 2020, INTERD T GERONT GERI, V43, P193, DOI 10.1159/000504481
  • [6] The History of Nanoscience and Nanotechnology: From Chemical-Physical Applications to Nanomedicine
    Bayda, Samer
    Adeel, Muhammad
    Tuccinardi, Tiziano
    Cordani, Marco
    Rizzolio, Flavio
    [J]. MOLECULES, 2020, 25 (01):
  • [7] Bhushan B., 2017, SPRINGER HDB NANOTEC, P1, DOI DOI 10.1007/978-3-662-54357-3_1
  • [8] Cabrini D.A., 2011, EVID-BASED COMPL ALT
  • [9] MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension
    Carregal-Romero, Susana
    Fadon, Lucia
    Berra, Edurne
    Ruiz-Cabello, Jesus
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [10] Effect of particle size on the biodistribution, toxicity, and efficacy of drug-loaded polymeric nanoparticles in chemoradiotherapy
    Caster, Joseph M.
    Yu, Stephanie K.
    Patel, Artish N.
    Newman, Nicole J.
    Lee, Zachary J.
    Warner, Samuel B.
    Wagner, Kyle T.
    Roche, Kyle C.
    Tian, Xi
    Min, Yuanzeng
    Wang, Andrew Z.
    [J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2017, 13 (05) : 1673 - 1683